Alligator Bioscience and Orion Corporation announce the initiation of the second program of their Immuno-oncology Research Collaboration and License Agreement

by | Jan 3, 2023

Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces an expansion to its research collaboration and license agreement with Orion Corporation, a global pharmaceutical company based in Finland, to discover and develop together new bispecific antibody cancer therapeutics. The collaboration has been expanded to add the development of a second bispecific antibody using Alligator’s proprietary bispecific RUBY™ platform, where Alligator will provide validated monospecific binders for one target and Orion will do the same for the other target.

Press inquiries should be adressed to:

Claus Andersson, PhD

General Partner